Printer Friendly

Japanese Clinical Trial Tests Dental Pulp Stem Cell-based Stroke Treatment.

TOKYO, Japan, February 6, 2019 -- Teijin Limited and JCR Pharmaceuticals Co., Ltd. announced that JTR-161, an allogeneic regenerative medical product comprising dental pulp stem cells (DPCs), was administered to the first patient in Japan-based Phase 1/2 clinical trials, in acute cerebral infarction (stroke).

Teijin and JCR signed a co-development and license agreement for JTR-161 in Japan in July 2017.

The trial is examining the safety and effectiveness of intravenously administered JTR-161 for patients who have suffered acute cerebral infarction.

Teijin Pharma Limited, the core company of the Teijin group's healthcare business, will conduct clinical studies and JCR will manufacture the investigational JTR-161 product for the clinical trials.

Teijin and JCR expect that JTR-161 contributes to the quality of life of patients as a new treatment option for acute cerebral infarction.

It is composed of DPCs isolated from human teeth, of which extraction is less invasive than bone marrow extraction and are available in Japan.

DPCs are also considered to pose a minimal risk of immunological rejection. JTR-161 is expected to demonstrate its effective suppression of inflammation by immune regulatory factors as well as promotion of regenerating organs by trophic factors.

Teijin and JCR will continue collaborating in joint research and development to eventually launch a commercial product as quickly as possible.

Teijin (TSE:3401) operates in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT.

The group has some 170 companies and around 19,000 employees spread out over 20 countries worldwide. It posted consolidated sales of $7.6 billion and total assets of $9 billion) in the fiscal year ending March 31, 2018.

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases.

Contact: http://www.teijin.com

Contact: http://www.jcrpharm.co.jp

COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:In The Clinic...
Publication:Stem Cell Research News
Geographic Code:9JAPA
Date:Mar 11, 2019
Words:333
Previous Article:Canadian Firm Says UC Davis Health Is New Site For Phase 2 CLI Trial.
Next Article:Final Patient Dosed In Phase 3 Heart Failure Trial.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters